155 related articles for article (PubMed ID: 23852268)
1. Changes in specialists' perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination: then and now.
Matloff ET; Bonadies DC; Moyer A; Brierley KL
J Genet Couns; 2014 Apr; 23(2):164-71. PubMed ID: 23852268
[TBL] [Abstract][Full Text] [Related]
2. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination.
Matloff ET; Shappell H; Brierley K; Bernhardt BA; McKinnon W; Peshkin BN
J Clin Oncol; 2000 Jun; 18(12):2484-92. PubMed ID: 10856109
[TBL] [Abstract][Full Text] [Related]
3. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.
Kuerer HM; Hwang ES; Anthony JP; Dudley RA; Crawford B; Aubry WM; Esserman LJ
Ann Surg Oncol; 2000 Jun; 7(5):325-32. PubMed ID: 10864338
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
5. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
6. Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations.
Kauff ND; Scheuer L; Robson ME; Glogowski E; Kelly B; Barakat R; Heerdt A; Borgen PI; Davis JG; Offit K
Genet Med; 2001; 3(6):422-5. PubMed ID: 11715007
[TBL] [Abstract][Full Text] [Related]
7. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
9. Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
Ann Intern Med; 2006 Mar; 144(6):I40. PubMed ID: 16549849
[No Abstract] [Full Text] [Related]
10. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
Hurry M; Eccleston A; Dyer M; Hoskins P
Int J Technol Assess Health Care; 2020 Apr; 36(2):104-112. PubMed ID: 32423520
[TBL] [Abstract][Full Text] [Related]
11. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
12. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
13. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
Morgan D; Sylvester H; Lucas FL; Miesfeldt S
Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
[TBL] [Abstract][Full Text] [Related]
14. Choice of management of southern Chinese BRCA mutation carriers.
Kwong A; Wong CH; Shea C; Suen DT; Choi CL
World J Surg; 2010 Jul; 34(7):1416-26. PubMed ID: 20182723
[TBL] [Abstract][Full Text] [Related]
15. Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.
Carpenter KM; Eisenberg S; Weltfreid S; Low CA; Beran T; Stanton AL
Health Psychol; 2014 Sep; 33(9):1003-11. PubMed ID: 23772886
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
[TBL] [Abstract][Full Text] [Related]
17. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
18. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic surgery for women at high risk for breast cancer.
Blanchard DK; Hartmann LC
Clin Breast Cancer; 2000 Jul; 1(2):127-34; discussion 135. PubMed ID: 11899651
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
Norum J; Hagen AI; Maehle L; Apold J; Burn J; Møller P
Eur J Cancer; 2008 May; 44(7):963-71. PubMed ID: 18362067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
